Docetaxel Plus ADT in Minority Patients With Prostate Cancer
Posted: Monday, July 20, 2020
According to research published in the American Journal of Therapeutics, the addition of upfront docetaxel to androgen-deprivation therapy (ADT) does not appear to result in improved survival outcomes in non-White patients with metastatic castration-sensitive prostate cancer. Combination upfront docetaxel and ADT had previously been found to improve survival outcomes in predominantly white patient populations.
“Although further study with a larger sample size is needed, these results underscore the imperative to ensure that clinical trials endeavor to enroll racially and ethnically diverse patient populations who are reflective of the real-world setting,” concluded Surabhi Pathak, MD, of the John H. Stronger, Jr Hospital of Cook County, Chicago, and colleagues.
The retrospective study included patients of ethnicities other than White who had been treated with either upfront docetaxel and ADT between January 2014 and December 2017 (n = 44) or with ADT alone between January 2008 and January 2017 (n = 38). At a median follow-up of 14 months for the docetaxel group and 42 months for the monotherapy group, the median progression-free survival was comparable between the two treatments (16 months vs. 18 months, respectively), including for patients with high-volume disease (16 months vs. 14 months, respectively). Moreover, in univariate analysis, the hazard ratio was 0.88 for upfront docetaxel plus ADT versus ADT alone and 0.81 for the time to nadir PSA (per month unit).
Anemia and fatigue were the most frequently reported adverse events in the docetaxel group. Among all patients, 76.8% (n = 63) were Black and 19.5% (n = 16) were Hispanic. Most patients enrolled in the study had high-volume disease (67%).
Disclosure: For full disclosures of the study authors, visit journals.lww.com.
